Sign in4 stories
The company said one cGMP-manufactured batch of 5mg psilocybin capsules will serve both its Health Canada-approved Phase 2 depression trial and existing commercial clinics in Australia.
SEC filing
The appointment supports Optimi's planned Phase 2 psilocybin trial for major depression and Phase 3 MDMA trial for PTSD, both expected to start enrolling in 2027.
SEC filing (3)
Dane Stevens acquired the shares at CDN$6.70 apiece on August 5, 2026, using an entity he controls.
SEC filing
The purchases, made indirectly through a controlled company, lifted Stevens' beneficial holdings to 452,547 shares.
SEC filing